170 related articles for article (PubMed ID: 11217362)
1. Quantification of immunotoxin number for complete therapeutic response.
Kreitman RJ
Methods Mol Biol; 2001; 166():111-23. PubMed ID: 11217362
[No Abstract] [Full Text] [Related]
2. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
Batra JK; Jinno Y; Chaudhary VK; Kondo T; Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8545-9. PubMed ID: 2510169
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri RK
Methods Mol Biol; 2001; 166():155-76. PubMed ID: 11217365
[No Abstract] [Full Text] [Related]
4. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
5. The interleukin-2 receptor: a target for immunotherapy.
Waldmann TA; Goldman C; Top L; Grant A; Burton J; Bamford R; Roessler E; Horak I; Zaknoen S; Kasten-Sportes C
Adv Exp Med Biol; 1992; 323():57-66. PubMed ID: 1485565
[No Abstract] [Full Text] [Related]
6. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein.
Fischer PH; Bird RE; Kasprzyk PG; King CR; Turner NA; Pastan I; Kihara A; Batra J
Adv Enzyme Regul; 1994; 34():119-28. PubMed ID: 7942269
[TBL] [Abstract][Full Text] [Related]
8. Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.
Nagai T; Tanaka M; Hasui K; Shirahama H; Kitajima S; Yonezawa S; Xu B; Matsuyama T
Clin Exp Immunol; 2010 Aug; 161(2):348-56. PubMed ID: 20550546
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
10. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
11. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
Kreitman RJ; Pastan I
Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of cancer with recombinant immunotoxins.
Pastan I
Biochim Biophys Acta; 1997 Oct; 1333(2):C1-6. PubMed ID: 9395287
[No Abstract] [Full Text] [Related]
14. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
[TBL] [Abstract][Full Text] [Related]
16. The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein.
King CR; Fischer PH; Rando RF; Pastan I
Semin Cancer Biol; 1996 Apr; 7(2):79-86. PubMed ID: 8740563
[TBL] [Abstract][Full Text] [Related]
17. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered proteins for immunoregulation.
Strom TB; Steele AW; Nichols J
Transplant Proc; 1995 Oct; 27(5 Suppl 1):18-20. PubMed ID: 7482811
[No Abstract] [Full Text] [Related]
19. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
20. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
